I'm a long term holder in several Pharmas, including LLY and MRK. Dropped PFE, BMY, and JNJ in the past year or two.
The administration clearly has PBMs in its' crosshairs, and pharma margins overall are likely to come down. Are healthcare providers (UNH and others) agnostic on this issue? I know little to nothing about the inner workings of their pricing models, but is there anyone on the board who would care to explain it to us like we're 5th graders?
At a surface level, it appears Trump wants to reduce end prices paid by Americans relative to other countries. Is this possible with the current system, or will there need to be some form of legislated price controls to achieve this objective? I think the idea that R&D costs be borne equally among all end users world-wide sounds good to most people, but I am unsure how this works practically.
The administration clearly has PBMs in its' crosshairs, and pharma margins overall are likely to come down. Are healthcare providers (UNH and others) agnostic on this issue? I know little to nothing about the inner workings of their pricing models, but is there anyone on the board who would care to explain it to us like we're 5th graders?
At a surface level, it appears Trump wants to reduce end prices paid by Americans relative to other countries. Is this possible with the current system, or will there need to be some form of legislated price controls to achieve this objective? I think the idea that R&D costs be borne equally among all end users world-wide sounds good to most people, but I am unsure how this works practically.